Evidence map›Paper›PMID 38919545›Full record

ArticleFrontiers in cardiovascular medicine2024

Left ventricular structure and function following renal sympathetic denervation in patients with HFpEF: an echocardiographic 9-year long-term follow-up.

Alexander Vogt, Alexander Plehn, Carlo Atti, Michael Nussbaum, Jörn Tongers, Daniel Sedding, Jochen Dutzmann

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Ultrasound renal denervation for treatment-resistant hypertension with severe left ventricular hypertrophy.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  2. Review
  3. Review
  4. The Role of Renal Denervation in HFpEF.Journal of clinical medicine · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander VogtDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Alexander PlehnDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Carlo AttiDepartment of Internal Medicine, Medical University Graz, Graz, Austria.
Michael NussbaumDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Jörn TongersDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Daniel SeddingDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Jochen DutzmannDepartment of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: High blood pressure is a major risk factor for cardiac remodeling and left ventricular hypertrophy, increasing cardiovascular risk and leading to heart failure with preserved ejection fraction (HFpEF). Since renal sympathetic denervation (RDN) reduces blood pressure in the long term, we aimed to investigate the long-term effect of RDN in patients with HFpEF in the present analysis. Methods: Patients previously enrolled in a local RDN registry who underwent high-frequency RDN with the use of the Symplicity Flex® renal denervation system between 2011 and 2014 were followed up. The patients were assessed by 24-h ambulatory blood pressure measurement, transthoracic echocardiography, and laboratory tests. We used the echocardiographic and biomarker criteria of the Heart Failure Association (HFA)-PEFF (Pre-test assessment, Echocardiography and Natriuretic Peptide Score, Funkctional testing, and Final aetiology) score to identify patients with HFpEF. Results: Echocardiographic assessment was available for 70 patients at a 9-year long-term follow-up. Of these patients, 21 had HFpEF according to the HFA-PEFF score. We found a significant reduction of the HFA-PEFF score from 5.48 ± 0.51 points at baseline to 4.33 ± 1.53 points at the 9-year follow-up ( Conclusions: The present analysis suggests that RDN may lead to a regression of the extent of HFpEF beyond a reduction in blood pressure and thus possibly contribute to an improvement in prognosis. More detailed information will be provided by ongoing randomized sham-controlled trials.

Indexed as

echocardiographyheart failure with preserved ejection fractionhypertensionlong-term follow-uprenal sympathetic denervation

Identifiers

PMID38919545
PMCPMC11196750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.